Short answer
Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Vaxcyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026, with full results in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- VAX-31 adult Phase 3 fully enrolled with 6,191 participants, supporting pivotal OPUS-1 topline data expected in Q4 2026
- OPUS-2 and OPUS-3 results expected in H1 2027, alongside manufacturing consistency work needed for planned BLA submission
- Cash, cash equivalents and investments $2.508B as of June 30, 2026, supporting clinical, manufacturing and commercial-readiness spending
- Q2 R&D expense $267.9M vs $194.2M, driven by VAX-31 trials, manufacturing preparation and expanded personnel
- Q2 net loss $284.3M, or $1.97 per share, vs $166.6M, or $1.22 per share, reflecting sharply higher development spending
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vaxcyte, Inc. 8-K filings
Get the next PCVX 8-K as it lands
Follow PCVX for push alerts, or ask the research agent what this filing means.